Cystic Fibrosis Patients with F508del/Minimal Function Genotype: Laboratory and Nutritional Evaluations after One Year of Elexacaftor/Tezacaftor/Ivacaftor Treatment

Elexacaftor/Tezacaftor/Ivacaftor in Patients with Cystic Fibrosis Homozygous for the F508del Mutation and Advanced Lung Disease: A 48-Week Observational Study

(2022) Vincenzo Carnovale et al.   Journal of Clinical Medicine

Impaired cholesterol metabolism in the mouse model of cystic fibrosis. A preliminary study

(2021) Felice Amato et al.   PLoS One

CFTR Modulator Therapy with Lumacaftor/Ivacaftor Alters Plasma Concentrations of Lipid-Soluble Vitamins A and E in Patients with Cystic Fibrosis

(2021) Olaf Sommerburg et al.   Antioxidants

State of the Art on Approved Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Modulators and Triple-Combination Therapy

(2021) Aniello Meoli et al.   Pharmaceuticals

Effectiveness and safety of elexacaftor/tezacaftor/ivacaftor in patients with cystic fibrosis and advanced lung disease with the Phe508del/minimal function genotype

(2021) Vincenzo Carnovale et al.   RESPIRATORY MEDICINE

A Therapy for Most with Cystic Fibrosis

(2020) Christine E. Bear   CELL

Tezacaftor/ivacaftor in people with cystic fibrosis heterozygous for minimal function CFTR mutations

(2020) Anne Munck et al.   Journal of Cystic Fibrosis

Lumacaftor/ivacaftor improves liver cholesterol metabolism but does not influence hypocholesterolemia in patients with cystic fibrosis

(2020) Monica Gelzo et al.   Journal of Cystic Fibrosis

The bidirectional relationship between CFTR and lipids

(2020) Kirsten A. Cottrill et al.   Communications Biology

Elexacaftor–Tezacaftor–Ivacaftor for Cystic Fibrosis with a Single Phe508del Allele

(2019) Peter G. Middleton et al.   NEW ENGLAND JOURNAL OF MEDICINE

Correction: The C-reactive protein/albumin ratio as an independent predictor of mortality in patients with severe sepsis or septic shock treated with early goal-directed therapy

(2019) Min Hyung Kim et al.   PLoS One

Daily Fructose Traces Intake and Liver Injury in Children with Hereditary Fructose Intolerance

(2019) Di Dato et al.   Nutrients

Multicenter validation study for the certification of a CFTR gene scanning method using next generation sequencing technology

(2018) Anne Bergougnoux et al.   CLINICAL CHEMISTRY AND LABORATORY MEDICINE

Supervised physical exercise improves clinical, anthropometric and biochemical parameters in adult cystic fibrosis patients: A 2-year evaluation

(2018) Ausilia Elce et al.   Clinical Respiratory Journal

VX-445–Tezacaftor–Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del Alleles

(2018) Dominic Keating et al.   NEW ENGLAND JOURNAL OF MEDICINE

Tezacaftor–Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del

(2017) Jennifer L. Taylor-Cousar et al.   NEW ENGLAND JOURNAL OF MEDICINE

C-reactive protein/albumin ratio is associated with lung function among children/adolescents with cystic fibrosis: a three-year longitudinal study

(2017) Julia Carvalho Ventura et al.   Sao Paulo Medical Journal

Role of CFTR in epithelial physiology

(2016) Vinciane Saint-Criq et al.   CELLULAR AND MOLECULAR LIFE SCIENCES

ESPEN-ESPGHAN-ECFS guidelines on nutrition care for infants, children, and adults with cystic fibrosis

(2016) Dominique Turck et al.   CLINICAL NUTRITION

Lumacaftor–Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del CFTR

(2015) Claire E. Wainwright et al.   NEW ENGLAND JOURNAL OF MEDICINE

Extensive Molecular Analysis of Patients Bearing CFTR-Related Disorders

(2011) Felice Amato et al.   JOURNAL OF MOLECULAR DIAGNOSTICS

Epidemiology and a novel procedure for large scale analysis of CFTR rearrangements in classic and atypical CF patients: A multicentric Italian study

(2008) R. Tomaiuolo et al.   Journal of Cystic Fibrosis